Trial Profile
A Phase IIIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Non-Squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Carboplatin; Cisplatin; Pembrolizumab; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms TRITON
- Sponsors AstraZeneca
- 19 Mar 2024 Planned initiation date (estimated date of first participant enrollment) changed from 28 Feb 2024 to 29 Mar 2024.
- 26 Feb 2024 Planned initiation date (estimated date of first participant enrollment) changed from 31 Jan 2024 to 28 Feb 2024.
- 30 Jan 2024 Planned initiation date changed from 29 Dec 2023 to 31 Jan 2024.